Compare Enveric Biosciences Inc (ENVB) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Roblox Corp — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Roblox Corp trades at $56.25 (market cap $40.86B). The key difference: Roblox Corp is far larger — about 7680.5× Enveric Biosciences Inc's market cap, and Roblox Corp is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | RBLX | |
|---|---|---|
Market Cap | $5.32M | $40.86B |
Sector | Health | Media |
52-Week High | $17.40 | $141.56 |
52-Week Low | $1.28 | $41.30 |
Enterprise Value | $408.82K | $39.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Roblox (RBLX) trades at $54.47, down 1.12% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The company shows strong revenue growth, reaching $4.89B in 2025, but continues to report significant net losses (-$1.07B). Analyst consensus is positive with a $59.62 price target, though multiple class action lawsuits create near-term legal overhang. Operating cash flow improved to $1.8B in 2025, supporting ongoing platform investments.
RBLX presents a growth-at-a-value story with robust user monetization potential offset by persistent profitability challenges. The stock offers upside to analyst targets but faces execution risks from legal proceedings and the need to translate revenue growth into sustainable earnings. Investor focus remains on Q3 2026 DAU recovery and margin improvement prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
